# Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate Cancer

> **NIH NIH R01** · WASHINGTON UNIVERSITY · 2022 · $673,467

## Abstract

Of the 33,330 men who died from prostate cancer in United States last year, over 80% of these patients
presented with localized disease. Thus, a majority of PCa patients are diagnosed at a potentially curable stage
and are often treated with radical prostatectomy (RP). Following RP, patients with aggressive disease face the
risk of prostate cancer recurrence, which manifests as persistently elevated or increasing serum PSA. While
salvage radiation therapy (RT) represents a standard treatment option for post-surgical recurrences, it results in
long-term disease control in only 30-40% of patients. Thus, the post-surgical recurrence state presents multiple
opportunities to improve patient care by addressing three critical challenges: (1) determining which patients will
benefit from the addition of androgen deprivation therapy (ADT), (2) identifying which patients treated with RT
and ADT will require further treatment intensification, and (3) identifying the appropriate treatment intensification
strategy for RT and ADT treated patients. Since androgen-directed therapies represent the backbone of
treatment for PCa (that have progressed through local therapies) the RTOG 96-01 and RTOG 05-34 phase III
clinical trials represent a unique resource of banked prostatectomy cohorts from patients that were randomized
to the presence or absence of treatment with ADT. For patients whose clinical and pathologic features place
them at highest risk of dying from PCa, these landmark trials have defined the standard of care by showing that
the addition of ADT to RT resulted in significant improvements to patient survival compared to RT alone. This
presents an unparalleled opportunity to develop and validate predictive and prognostic biomarkers addressing
multiple unmet clinical needs throughout patient care following surgery. Aim 1 will focus on using high-throughput
DNA and RNA sequencing to develop a predictive classifier for identifying which patients would benefit from ADT
using patients from RTOG 96-01 and 05-34. In Aim 2 we will develop and validate a prognostic classifier that
integrates genomic and clinicopathologic data for PCa patients treated with RT+ADT that may benefit from
treatment intensification. Aim 3 will focus on identifying RT+ADT patients requiring treatment intensification that
could benefit from receiving pelvic lymph node radiation therapy using patients from RTOG 05-34. The proposed
study would have significant impact by developing and optimizing prognostic and predictive biomarkers that
could have enormous potential for rapid clinical translation to personalize therapy and transform the
management of PCa patients following surgery.

## Key facts

- **NIH application ID:** 10366451
- **Project number:** 1R01CA260066-01A1
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Jingqin Luo
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $673,467
- **Award type:** 1
- **Project period:** 2022-01-01 → 2026-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10366451

## Citation

> US National Institutes of Health, RePORTER application 10366451, Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate Cancer (1R01CA260066-01A1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10366451. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*